Analyst Scoreboard: 4 Ratings For Certara

Ratings for Certara CERT were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $17.38, a high estimate of $19.00, and a low estimate of $15.50. Observing a 15.87% increase, the current average has risen from the previous average price target of $15.00.

Decoding Analyst Ratings: A Detailed Look

An in-depth analysis of recent analyst actions unveils how financial experts perceive Certara. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Certara. This information offers a snapshot of how analysts perceive the current state of the company.
• Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Certara compared to the broader market.
• Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Certara's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.

To gain a panoramic view of Certara's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

Stay up to date on Certara analyst ratings.

About Certara

Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The group has a business presence in the United States, EMEA, and other regions, of which a majority of revenue is derived from the United States.

Financial Insights: Certara

Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.

Revenue Growth: Over the 3 months period, Certara showcased positive performance, achieving a revenue growth rate of 1.03% as of 30 September, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Certara's net margin excels beyond industry benchmarks, reaching -57.22%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): Certara's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -4.56%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): Certara's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -3.16%, the company showcases efficient use of assets and strong financial health.

Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.29.

How Are Analyst Ratings Determined?

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

This article was generated by Benzinga's automated content engine and reviewed by an editor.